France· FR:68516450
SCINTIMUN 1 mg trousse pour préparation radiopharmaceutique
A medicinal product containing besilésomab, registered in France by TELIX INNOVATIONS (BELGIQUE).
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- BESILÉSOMAB
- Manufacturer
- TELIX INNOVATIONS (BELGIQUE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
- cip1334009576913631 flacon(s) en verre - 1 flacon(s) en verre
- cip1334009576914242 flacon(s) en verre - 2 flacon(s) en verre
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Besilésomab in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsScintimun, 1mg kit voor radiofarmaceutisch preparaatTelix Innovations S.A.
- CzechiaSCINTIMUNTelix Innovations, Herstal
- SwitzerlandScintimun, Markierungsbesteckb.e.imaging.ag
- SpainSCINTIMUN 1 mg, EQUIPO DE REACTIVOS PARA PREPARACION RADIOFARMACEUTICATelix Innovations
- FinlandScintimunTelix Innovations
- United KingdomScintimun 1mg kit for radiopharmaceutical preparationCurium Pharma UK Ltd
- IrelandScintimun 1 mg kit for radiopharmaceutical preparationTelix Innovations
- IcelandScintimunTelix Innovations
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Scintimun
- Liechtenstein · Scintimun
- Norway · Scintimun
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/93895bb5-a7f2-48a2-b351-cb8378594e9e GET /v1/drugs/93895bb5-a7f2-48a2-b351-cb8378594e9e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "68516450",
"date_amm": "2010-01-11",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/09/602",
"substance": "BESILÉSOMAB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "trousse et trousse pour préparation radiopharmaceutique",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about besilésomab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.